In reproductive medicine, GLP-1 receptor agonists were initially conceptualised in early integrative and narrative studies primarily as metabolic agents that indirectly improved ovulatory function and fertility by facilitating weight loss, insulin sensitisation, and systemic endocrine normalisation in obese women and patients with PCOS. The gene discussed is INS; the disease is polycystic ovary syndrome.